Gut microbiota in the pathogenesis and therapeutic approaches of diabetes

The gut-liver axis plays a prominent role in the pathogenesis and therapy of metabolic diseases such as diabetes. The intestinal specific origin of several hormones that guide both inter-and post-prandial metabolism of carbohydrates and lipids, drives the attention of scientists and clinicians on the gut as a major site to intervene with novel diagnostic or prognostic markers. The role of intestinal ecology in the metabolic syndrome was postulated when gut microbiota was directly connected with inflammation, hyperinsulinemia, and diabetes. There have been several discoveries with the role of gut microbiota and gut-liver axis in diabetes. Also, there are several trials ongoing on the therapeutic efficacy of probiotic administration in diabetes and its complications. Here we point to the metabolic action of microbiota and discuss the actual state of the art on gut microbiota as a novel prognostic biomarker with a putative therapeutic role in diabetes. Copyright (c) 2023 The Author(s). Published by Elsevier B.V.

Automated summary

The gut-liver axis plays a significant role in the development and treatment of diabetes, and the gut microbiota is a key factor. There are ongoing studies evaluating the therapeutic efficacy of probiotics in diabetes and its complications.